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vABSTRACT
MSX1 reprograms melanocytes into neural crest-like stem cells and promotes melanoma
progression.
Joshua X. Wang
Differentiation from stem cells to lineage-specific somatic cells is not a unidirectional
process, but can be reverted by genetic and/or epigenetic alterations. Here, we show
that the homeodomain transcription factor Msh homeobox 1 (MSX1), which is es-
sential for neural crest specification, reprograms melanocytes towards a neural crest
precursor-like state. MSX1-expressing melanocytes express the neural crest marker
p75 neurotrophin receptor and are able to differentiate into neuronal and mesenchy-
mal lineages. Mechanistically, MSX1 binds and suppresses the proximal promoter of
microphthalmia-associated transcription factor (MITF), the master transcriptional
regulator of melanogenesis. Expression of MSX1 is significantly correlated with
melanoma progression, as overexpression of MSX1 prompts melanoma cell motility
and depletion of MSX1 significantly inhibits melanoma migration. Taken together,
these results demonstrate that neural crest-like reprogramming in melanocytes can
be achieved by a single factor and that similar dedifferentiation is a critical process
for melanoma progression.
1CHAPTER 1: INTRODUCTION
Metastatic melanoma is a highly aggressive disease that is currently without a
cure. Targeted therapies and immunotherapies exist and are proven to be effective
after radiation or chemotherapy have failed; however, despite modern advances in
drug development, the positive effects are potent only in a small subset of the disease
and are accompanied by substantially toxic side effects. Part of the reason why
present day therapies have failed is that understanding the mechanisms of melanoma
progression still remains to be discovered. Here, using a novel indirect approach by
studying normal skin biology, a possible new mechanism for melanoma metastasis
is identified by drawing upon the similarities between neural crest stem cells and
malignant melanoma.
1.1 Melanoma overview
1.1.1 Etiology
Cancer begins when cells begin to grow uncontrollably instead of dying, and
melanoma is a cancer of the skin. The differences between cancers of various tis-
sues are vast and there is no one all-encompassing definition. There are, however,
six hallmarks of cancer that describe the complexity and sophistication with which
this malignancy evolves: self-sufficiency in growth signals, insensitivity to anti-growth
signals, evading apoptosis, limitless replicative potential, sustained angiogenesis, and
tissue invasion and metastasis1. Consequently, cancer is a disease that results in the
abnormal regulation of all genes that control cellular biology.
The risk of melanoma can be inherited in some patients; however, most cases
of melanoma (about 90%) are sporadic. Environmental and lifestyle factors such
as exposure to ultraviolet (UV) radiation, carcinogenic chemicals, etc., can cause
DNA damage and subsequent mutations. Melanoma arises when that results in the
aberrant expression of various oncogenes controlling cell proliferation in normal skin
cells. It should be noted that these environmental and lifestyle risk factors do not
2necessarily denote the onset of skin cancer; susceptibility can vary from individual
to individual. Often times, the environmental risk factors are compounded by an
individuals genetic composition. Inherited traits such as skin, hair, and eye color,
resistance to tanning, and pre-existing mutations in passenger genes may increase
or accelerate ones susceptibility to melanoma. For example, while having red hair
and freckles does not give rise to melanoma per se, when associated with a lifestyle
of frequent tanning and exposure to UV rays, the chances of acquiring melanoma
drastically increases. Moreover, chronic exposure to risk conditions may take years
before the first signs of malignancy are detected, at which point, a lifestyle change
may be ineffective.
1.1.2 Epidemiology
Melanoma incidence rates have steadily increased over the past 30 years, with an
estimated 76,690 new cases to be diagnosed in the US in 20132. As fashion trends veer
towards tanned skin, more and more individuals are engaging in prolonged outdoors
activity under the sun and using tanning salons. This leads to an increased risk of
melanoma among those younger than 652; however, incidence rates are greater in
those 65 and older due to the fact that the damage takes many years to accumulate.
While incidence rates are on the rise for melanoma, almost tripling from 7.89 to 23.58
per 100,000 from 1975 to 2010, the death rate has remained consistent at just below
3 deaths per 100,000 people for the past 30 years despite overwhelming advances in
discovery and treatment.
Melanoma is more common in whites than in blacks. The overall lifetime risk of
being diagnosed with melanoma is 2% for whites, 0.16% for Asians/Pacific Islanders,
and 0.1% for blacks. At the same time, the mortality rate for males is 4.1 and 1.7 for
females, making melanoma a very deadly disease for older white men.
31.1.3 Staging
While all cancers have four stages, melanoma is unique in the fact that the
early stages are curable by surgical removal. However, once melanoma reaches the
later stages, especially metastasis, there is no cure. Current treatments spanning
from chemotherapy to molecularly targeted therapy are ineffective against metastatic
melanoma. Melanomas of the skin are thought to arise from a single melanocyte.
These cells are responsible for pigmentation and reside between the epidermis, the
outermost later of the skin, and the basement membrane, the next layer. In stage 0
melanoma, also known as “melanoma in situ,” the malignant cells are confined to the
epidermis and the basement membrane is still intact. This lesion is a benign nevus
and is treated with surgical excision with 5mm to 15mm margins (Clark surgical in-
tervention), and no further intervention is necessary. This is performed to ensure that
the melanoma has not spread beyond the visible lesion. Clinical stage 1 melanoma
tumors are less than 1mm thick and are still removed through surgery. The likelihood
of the cancer spreading to other parts of the body is very low since the cells have not
yet reached the deeper tissue or surrounding blood vessels.
The tumor begins to grow first upwards towards the epidermis, before expanding
vertically down towards the deeper layers of the dermis. Stage II melanoma is marked
by a thickness over 4mm, however, this tumor has grown more aggressive. The
melanoma still has not spread to any lymph organs, but its likelihood of spreading
has increased dramatically. Standard procedure is wide-local excision to remove the
diseased skin. Ten-year survival rates range from 50% to 70%, and depending on the
severity, the attending physician may request a sentinel lymph biopsy. Melanomas of
this type should be carefully followed, as the cells have begun to grow more invasively
(radial and vertical spreading).
The classification criteria until this point have been based on tumor thickness.
Stage III melanoma, however, is characterized when tumor cells reach one or more of
4the surrounding lymph nodes, and is determined by the number and size of metastatic
nodes. This represents a significant advancement in the disease, as the cells that have
taken up colony at the lymph nodes pose a drastic risk. Pathologically, these metas-
tases are entirely different from the primary tumor, and thus require a different treat-
ment strategy. Whereas the primary tumor was mainly concerned with belligerent
growth, metastatic cells must possess a certain finesse for more specialized tasks. For
instance, the main method of metastatic dissemination is via the lymphatic and/or
the blood vessels. In order to do so, cancer cells must be able to penetrate the walls
and withstand the high sheer forces present in the blood vessels. Moreover, in ad-
dition to intravasation and extravasation, metastatic cells must be able to colonize
and form a secondary tumor. Therapeutic practices at this stage still include surgical
intervention by lymphadenectomy, however this can have significant consequences for
the patient. While removal of one or more positive lymph nodes can greatly reduce
the number of metastatic cells in the local region surrounding the lesion, there can
still exist smaller groupings of cells that were undetected. Broad range treatments
involving chemotherapy or immunotherapy are used to eradicate any remaining cells
that contain tumor-forming potential.
In the final stage, the cancer has metastasized to distant areas of the body and
becomes very hard to cure. Not only have the number of tumor sites increased,
but also each affected organ contains multiple micro and macro metastases. Surgical
intervention is nigh impossible at this point.
1.1.4 Therapy
Targeted therapy represents a significant advancement compared to standard
chemotherapy practices. Late stage melanoma cannot be cured by chemotherapy or
radiation, as the disease has disseminated too much. Chemotherapy is often accom-
panied with radiation and targets cells that rapidly divide, including normal healthy
cells in the bone marrow, digestive tract, and hair follicles. Consequently, destroy-
ing those healthy cells leads to side effects such as immune suppression, nausea, and
5physical changes like hair loss. Targeted therapies, on the other hand, allow sys-
temic delivery of a drug directed at a specific molecular interaction. Mutant BRAF
is an oncogenic driver of increased proliferation in over 50% of melanomas and leads
to increased MAPK pathway activity3,4. Vemurafenib, a kinase inhibitor directed
at the mutated V600 form of BRAF, targets the mutated binding pocket and inac-
tivates downstream signaling of the pathway5,6. Moreover, the drug is only active
in patients with this mutated melanoma. In patients with unresectable metastatic
melanoma, treatment with vemurafenib increased survival time by over 6 months and
reduced the number of metastatic tumors7,8. Other similar drugs work in the same
way by inhibiting specific protein-protein interactions within the cell. These drugs
pose an advantage over traditional chemotherapy by being able to not only select for
the melanoma cells and not the healthy cells, but also to target a specific pathway
involved in abnormal activity.
Melanoma is also a highly immunogenic disease, and many mechanisms of eva-
sion involve shutting down the immune systems response. Antigens produced by
melanoma are recognized by dendritic cells and presented to cytotoxic T lympho-
cytes (CTLs) for subsequent removal. However, the dendritic cells also present an
inhibitory antigen that binds to the CTLA-4 receptor on the CTLs. Melanoma is able
to survive through inactivation of the immune system in this way. Ipilimumab, a hu-
man monoclonal antibody against CTLA-4 blocks the inhibitory signal on the CTLs,
allowing for cytotoxic removal. The addition of the antibody prevents the antigen
from binding to the CTL receptor, blocking the inhibitory signal and allowing the
lymphocytes to destroy the cancer cells. Once again, this specialized immunotherapy
is able to pinpoint its efficacy towards a cancer specific interaction rather than a
broad system wide treatment like chemotherapy.
Despite the giant leap forward in treatment by targeted therapies, they do include
downsides. In vemurafenibs case, although melanoma tumors initially receded, they
come back due to resistance to the drug9. Often times, these tumors that come back
6are resistant to the inhibitor and develop secondary mutations9. Treatment can be
combined with a second inhibitor, but little is known about the effects of two or
more inhibitors and the context in which it is effective. Moreover, the side effects of
the drugs are highly toxic. Adverse events include rash, photosensitivity, pruritus,
skin papilloma, skin and liver toxicities, fatigue, and the development of cutaneous
squamous cell carcinomas5,7,10,11. Present-day therapies are able to prolong a patients
life, however, this is only by a few months, and, not to mention, the treatments are
increasingly expensive. Immunotherapies also have their own downsides. The nature
of targeted immunotherapy is to overcome the immunoediting brought on by the
tumor. As such, response rates take much longer when compared to chemotherapeutic
agents, and during this time, the melanoma continues to progress. Survival and
response rates for ipilimumab are also lower when compared to vemurafenib9,8.
The issue of recurring tumors with increased has prompted the field to study
the biology behind tumor maintenance and resistance. A tumor becomes resistant
to a specific inhibitor after alternate pathways are activated, making the primary
treatment futile. The inherent properties of the tumor, such as its heterogeneous
composition and phenotypic plasticity, prompted the following work and research
strategy.
1.2 Research strategy and melanoma models
1.2.1 Tumor heterogeneity
While an initial driver mutation in the primary tumor is responsible for excessive
growth, however, mutations in passenger genes are not constant throughout the tu-
mor. Melanoma is a heterogeneous tumor, even with tumors originating from a single
cell12. For the continuous growth, the tumor is capable of performing many tasks out-
side of normal cell maintenance, including angiogenesis, immune system suppression,
increased proliferation, etc. Similar to how the normal body has specialized cells to
perform specific actions (melanocytes produce pigment while neurons are designed to
propagate electrochemical potential), so the tumor has specialized and differentiated
7cells for its specific tasks. This heterogeneity leads to separate distinct populations
of cells with phenotypic and functional differences. Consequently, as the cells in the
tumor arise from a clonal population, a progenitor cell must exist that is able to give
rise to daughter cells.
The implication of how the tumor is organized consequently affects the strategy
for treatment. The first proposed model of cancer stem cells (CSCs) has been popular
in many forms of cancer13. In this model, the tumor is hierarchically organized, with
only CSCs able to initiate tumors upon transplantation. This cell can (1) continue
to divide and replicate, yielding identical daughter cells, or, (2) differentiate and
subsequently gives rise to more functional cells, much like how the progenitor cells of
various tissue types naturally do. Treatment of this type of tumor can be directed at
targeting CSCs, as these comprise of the bulk of the tumor and are the cells that can
give rise to new tumors.
On the other hand for a cancer like melanoma, the existence of a CSC has been
debated14–22, and a new dynamic stemness model has been proposed23. In this model,
rather than a mother cell able to give rise to differentiated cells at the top, all tumor
cells possess the ability to form new tumors, a distinct characteristic of CSCs. In
contrast, owing to their plastic nature, the cells undergo phenotype switching, al-
lowing them to shift from one cell state to another, and more importantly, from a
differentiated state towards a stem-like state23. This type of tumor is stochastically
organized while the mechanisms that govern switching from one state to another are
still unknown. The tumor is maintained by a temporarily distinct subpopulation of
slow cycling cells that express JARID1B. This has major implications for the way
melanoma is treated, as virtually all of the tumor cells must be eradicated to prevent
recurrence.
Regardless of which organizational model melanoma follows, many silenced de-
velopmental stem cell markers are re-expressed in melanoma. More specifically, as
part of the melanocytic lineage, many genes associated with neural crest induction
8and the migration of neural crest cells are active once again in melanoma24. These
pathways serve little purpose in terminally differentiated cells, as they do not need to
migrate to distal parts of the body; however, malignant melanoma hijacks many of
the embryonic migratory programs present in the neural crest. Our research strategy
is to study the biology of neural crest stem cells as a working model for melanoma.
After uncovering mechanisms that regulate stem cell maintenance and differentia-
tion, we hypothesize that these interactions are at work again in melanoma. This
method provides a unique approach at determining a novel therapeutic approach of
melanoma, while providing room for the discovery of novel biomarkers of melanoma.
1.2.2 Neural crest
The neural crest is a transient embryonic structure, unique to vertebrates, that
gives rise to neuronal and mesenchymal lineages. Neural plate development consists
of four stages: formation, bending, convergence, and closure. After gastrulation, part
of the ectoderm is specified into the neural plate by signaling from the dorsal meso-
derm cells directly underneath it25,26. A complex network of intermediate levels of
secreted BMP4 (bone morphogenetic protein 4) and Wnt signaling induces formation
of the neural plate from the non-neural ectoderm. The cells at the edge between the
ectoderm and neural tissue become the neural crest border cells that are responsible
for folding and closing the neural tube25,26. The border cells are regulated by the
expression of a set of transcription factors, including PAX3 and MSX125,26. Neural
folding occurs when opposite sides of the neural plate become elevated and begin to
come together towards the medial line. The neural plate folds over itself as the two
sides fuse, forming the neural tube.
The cells lateral to the ectoderm and immediately adjacent the dorsal neural tube
are neural crest cells and give rise to many lineages of the trunk and cranial25. These
neural crest stem cells (NCSCs) possess high migratory and multipotent potential25,26.
Many signals are required for maintenance of these stem cells. After leaving the neu-
ral tube and traveling to distant portions of the body, they differentiate into neurons,
9Figure 1.1: A) The neural plate (np) is specified by signaling from the surround-
ing cells, separating it from the non-neural ectoderm (gray). B) NP border
cells begin to come towards the medial line and form the neural fold (nf). C)
After opposite ends of the neural folds come together, they fuse and form the
neural tube (nt), separating from the ectoderm. D) The neural crest cells (nc)
reside between the neural tube and the ectoderm. They contain high migra-
tory potential and differentiate to various neural crest lineages at distal sites
(adapted from25).
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glial cells, cartilage, bone cells, connective tissue, cardiac cells, and melanocytes25.
Epithelial-mesenchymal transition (EMT) is an event required for neural tube forma-
tion and the generation of migratory NCSCs. This event is accompanied by the loss
of E-cadherin and the gain of N-cadherin and NCAM on the cell surface25,26. Cells
that have undergone EMT also express EMT transcription factors such as SNAIL
and SLUG. Morphologically, as a polar, epithelial cell detaches from its neighbors, it
gains a motile phenotype and becomes a spindle-shaped mesenchymal cell.
1.2.3 Melanoma shares stem cell properties
Figure 1.2: After Delta ligand binding to the Notch transmembrane receptor, the
intracellular portion is cleaved (Nicd) and translocates to the nucleus, where
it forms a transcriptional complex with CSL and MAML. In the absence of
Nicd, the complex resides at Notch target genes but represses transcriptional
activity. Notch target genes such as the HES or HEY families and c-Myc begin
transcription after Nicd binds to MAML (adapted from27)
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While melanoma and NCSCs remain distinct and separate cells, nonetheless, they
share similar properties with each other when compared to melanocytes and ker-
atinocytes. Melanoma cells often hijack and utilize developmental programs that are
active during embryogenesis. Moreover, melanoma exhibits a phenotypic plasticity
that allows for favorable genetic changes towards a proliferative or invasive phenotype,
much like an undifferentiated stem cell state.
Two such pathways that are re-expressed in melanoma are the Wnt and Notch
signaling pathways28. These are highly conserved developmental pathways depen-
dent on cell-cell ligand-receptor interactions. The Wnt pathway is responsible for
controlling embryonic processes that regulate body axis patterning, cell fate specifi-
cation, cell proliferation, and cell migration29–31. Three distinguished Wnt signaling
pathways have been identified: the canonical β-catenin-dependent pathway and the
non-canonical planar cell polarity and Wnt/calcium pathways. Similar to Wnt, the
Notch pathway is an ancient cell-signaling pathway found in multicellular organ-
isms32, responsible for governing a plethora of cell differentiation processes, more
notably, the maintenance of neural progenitor cells33–36. Notch exists as a single-pass
transmembrane receptor that, in vertebrates, is responsive to Delta and Jagged lig-
ands. Upon ligand-receptor binding, the intracellular portion of Notch is cleaved and
translocated to the nucleus. There, Notch forms a transcriptional complex with CSL
and Mastermind-like protein 1 (MAML1) before beginning transcription of Notch
target genes (HES and HEY families and Myc, among others).
Other groups have implicated Notch1 as an oncogene in T-cell acute lymphoblastic
leukemia (T-ALL), with more than 50% of T-ALLs harboring activating mutations37.
Its impact and role in melanoma, however, remains relatively unstudied. An initial
step in characterizing this pathway in melanoma showed Notch1 as a transforming
oncogene in melanocytes38. As active Notch1 expression is high in melanoma cells,
sequencing of 17 human melanoma cell lines within exons 26 and 34 of Notch1 showed
no genetic alterations, unlike what was previously seen in T-ALL. This signified that
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Notch pathway activation in melanoma is due not by insertional or missense mu-
tations, but rather, overexpression of Notch1. Ectopic expression of intracellular
Notch1 in melanocytes promoted cell growth and invasion. Moreover, these changes
were accompanied by morphological and phenotypic changes that included dendrite
shortening, growth in endothelial-like networks, and increased adhesion. On the other
hand, pan-inhibition of Notch signaling by dominant-negative MAML1 decreased cell
proliferation and motility in melanoma cells. As such, Notch signaling is important
for melanoma growth, motility, and acts as a regulator towards a transformed pheno-
type. The mechanisms that act upstream of the Notch cascade, i.e., initiate cell-cell
Notch signaling, remain to be discovered, however.
1.3 Previous work
1.3.1 Neural crest-like stem cells of the dermis
Previously, the Herlyn lab and others have discovered multipotent stem cells
within the human skin39–41. In tissue culture conditions, these cells are able to pro-
liferate, grow as cell clusters, and eventually form spheres from a single cell. They
also express a variety of embryonic and neural crest stem cell markers, such as Oct4,
NANOG, Nestin, and NGFR p75. Moreover, the cells possess the capability to dif-
ferentiate into neuronal and mesenchymal lineages, such as neurons, smooth muscle
cells, chondrocytes, adipocytes, and melanocytes41. This was verified by the loss of
NANOG and the gain of lineage specific markers, fulfilling the two tenets of stem cells:
the ability to proliferate indefinitely and the ability to differentiate into different cell
types42. Due to their keen similarities with NCSCs during development and their
neural crest lineage, we termed these adult stem cells as neural crest-like stem cells
(NCLSCs). While NCLSCs and their niche remain relatively uncharacterized, they
may serve as a reservoir of undifferentiated stem cells that become active in response
to tissue repair.
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1.3.2 A more pragmatic NCLSC model
Notchs role in melanoma has also been studied by the Herlyn lab in the context
of transforming melanocytes to a more stem-like phenotype. Ectopic expression of
Notch1 is sufficient to reprogram melanocytes to an undifferentiated, neural crest-like
multipotent stem cell state43. These induced NCLSC (iNCLSCs) are very similar
to the natural NCLSCs found previously in the dermis. When cultured in human
embryonic stem cell (hESC) media, the cells formed spheres and continued to divide,
an attribute that normal differentiated cells do not have. Moreover, the spheres
lost expression of melanocytic specific markers (MITF, TYRP1, HMB45, etc.) and
instead, gained expression of embryonic and neural crest markers (NGFR p75, SOX10,
Nestin). The iNCLSCs could also be differentiated into mesenchymal and neuronal
lineages, such as osteoblasts, neurons, smooth muscle cells, astrocytes, chrondrocytes,
and oligodendrocytes.
While the artificial induction of Notch is a few steps removed from embryonic
NCSCs during development, these cells can be cultured indefinitely in a homogeneous
population. Moreover, each stem cell contains its own niche environment, and as the
niche for NCLSCs has not yet been identified, culturing NCLSCs for too long prompts
spontaneous differentiation (unpublished data). Consequently, Notch1 reprogrammed
melanocytes are a functional equivalent to NCSCs, and are a viable and practical
model in studying differentiation and maintenance.
1.4 MSX1
Global gene expression analysis performed on iNCLSCs showed that MSX1, a
homeodomain transcription factor, was upregulated during the reprogramming pro-
cess. MSX1, or Msh homeobox 1, is a highly conserved basic helix-loop-helix tran-
scriptional repressor that is highly active in embryogenesis (reviewed here26). MSX1
is present at the neural plate border, promoting expression of early neural crest mark-
ers SNAIL, SLUG, and FOXD3 44. After neural tube closure, MSX1 is expressed at
14
the dorsal neural tube, and thought to be responsible for neural tube patterning and
development. Overexpression of MSX1 in myotubes has also been shown to dediffer-
entiate to a progenitor cell45. Based on such, we hypothesized that MSX1 is able to
induce melanocyte dedifferentiation in a similar manner as Notch1.
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CHAPTER 2: PROBLEM DEFINITION AND HYPOTHESIS
Melanoma is a complex disease involving many pathways that control cell growth,
motility, and differentiation. The molecular mechanisms that surround melanoma
progression are still unknown, however, metastatic melanoma utilizes many of the
embryonic invasion and migration programs. Furthermore, pathways that govern
differentiation and invasion in NCSCs are reactivated one again in melanoma. Study-
ing these pathways and how they are maintained is a novel strategy to discover yet
unknown relationships in melanoma. Previous studies from the Herlyn lab have iden-
tified a practical and functional model for NCSCs, and subsequently, revealed an
interesting candidate gene for further study. The role of MSX1 in neural crest de-
velopment poses an intriguing question for its role in melanoma, as it is involved in
regulating the specification and migration of neural crest cells. The data presented
below seeks to discover:
1. The role of MSX1 in melanocytes and melanoma. We hypothesize that ec-
topic expression of MSX1 is sufficient to dedifferentiate human melanocytes to
a precursor state. We also with to identify the mechanisms that MSX1 works
through.
2. The function of MSX1 in melanoma and whether it can contribute to an ag-
gressive phenotype in melanoma. Based on neural crest genes being involved
in malignant melanoma, and since MSX1 is a regulator of embryonic migra-
tion of neural crest cells, we hypothesize that MSX1 plays a role in melanoma
progression as a critical element in the migration program.
16
CHAPTER 3: RESULTS
3.1 MSX1 attenuates pigmentation and alters the expression of adhesion
molecules in melanocytes
We have previously identified NCLSCs existing in the dermis of human skin41
that display self-renewal capacity and the ability to be differentiated into multi-
ple neural crest-derived derivatives, including melanocytes. However, the molecular
mechanisms that maintain NCLSCs in an undifferentiated state are largely unknown.
NCLSCs expressed high endogenous levels of MSX1, whereas terminally differenti-
ated melanocytes barely expressed MSX1 (Figure 3.1a). The difference in expression
of MSX1 between NCLSCs and somatic pigment cells suggested the role of MSX1
in maintaining the neural crest-like state. We have also recently shown that termi-
nally differentiated melanocytes can be fully reprogrammed to multipotent NCLSCs
by the reactivation of Notch1-signaling. These cells lost pigmentation and the ex-
pression of E-cadherin43. We specifically investigated the potential of MSX1 to elicit
similar effects in melanocytes by stably expressing MSX1 in melanocytes using an
MSX1-coding lentiviral vector (pLU-EF1aL-MSX1-IRES-BLAST) (Figure 3.1b).
Figure 3.1: (a) High endogenous levels of MSX1 in dermal stem cells compared
to foreskin-derived melanocytes. (b) Stable exogenous expression of MSX1
in melanocytes (pLU-EF1aL-MSX1-IRES-BLAST) compared to cells infected
with the control virus. Detection of β-actin indicates even loading in both gels.
After 2 to 3 weeks of stable expression, we detected a dramatic decrease of pig-
mentation in MSX1-melanocytes (Figure 3.2). Most melanocytes (5 of 7 lines) that
were transduced with MSX1 lost macroscopic pigmentation even though pigmentation
levels varied from different donors.
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Figure 3.2: Cell pellets showing two different strains of melanocytes (FOM1,
FOM2) infected with pLU-EF1aL-MSX1-IRES-BLAST lose pigmentation com-
pared to control cells. This effect is consistent in most melanocytes transduced
with MSX1.
Figure 3.3: Immunoblot revealing the decreased expression of M-MITF in MSX1-
melanocytes from two different donors (left panel). The corresponding bands
to M-MITF were quantified and normalized to the loading control, β-actin.
Consistent with the overt decrease of pigmentation, M-MITF was strongly reduced
at the protein level in MSX1-melanocytes (Figure 3.3). Furthermore, mRNA levels of
M-MITF were diminished in these cells (Figure 3.4) suggesting that M-MITF is reg-
ulated on a transcriptional level and not by diverse post-translational modifications,
which can also regulate its activity46,47.
During development, tyrosinase is induced under the control of M-MITF and is di-
rectly correlated with the amount of pigmentation that occurs in primary melanocytes.
We observed that the expression of tyrosinase in MSX1-melanocytes decreased 60 to
80% compared to basal levels of control cells (Figure 3.4).
When MSX1-melanocytes were grown as an adherent monolayer, they lost the
characteristic melanocytic morphology consisting of long and smooth dendrites, and
instead, gained a mesenchymal-like appearance consisting of shorter dendrites and
a triangular shape (Figure 3.5a). In addition to the loss of pigmentation, ectopic
expression of MSX1 in melanocytes had a significant impact on the expression of
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Figure 3.4: qRT-PCR confirming the overexpression of MSX1 and the corre-
sponding decrease of M-MITF and Tyrosinase. Target gene mRNA levels were
normalized to GAPDH. Asterisks indicate p < 0.001.
cellular adhesion molecules, as E-cadherin expression was strongly reduced in MSX1-
melanocytes (Figure 3.5b).
Figure 3.5: (a) MSX1-melanocytes closely resemble mesenchymal populations
with shorter dendrites and a triangular shape, while control cells infected with
an empty vector display a typical melanocytic shape with long dendrites. Mor-
phologic changes were observed 2 to 3 weeks after selection. Scale bars: 200 µm
(b) Immunoblot revealing levels of E-cadherin (E-Cad) and neural cell adhesion
molecule (NCAM) from 3 different strains of melanocytes. There is a strong
inverse correlation between E-cadherin expression and MSX1. Simultaneously,
NCAM levels increased along with MSX1.
In fetal development, MSX1 acts immediately upstream of SNAIL and SLUG to
specify formation of the neural crest44. However, levels of both SNAIL and SLUG
remained unaltered in MSX1-melanocytes (data not shown). This suggested that
E-cadherin was reduced in a manner independent of SNAIL and SLUG. Likewise, we
did not detect an increase in the expression of either MelCAM or N-Cadherin (data
not shown), which are known to be associated with an invasive and migratory pheno-
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type in melanoma. However, ectopic expression of MSX1 in melanocytes consistently
increased the expression of neural cell adhesion molecule (NCAM), a transmembrane
glycoprotein that plays a central role in cell migration in the developing nervous
system and in mesenchymal stromal cells48–50 (Figure 3.5b). Altogether, exogenous
expression of MSX1 alone seems sufficient to impede the melanogenic activity of
melanocytes and cause a shift in the expression of adhesion molecules.
3.2 MSX1 elicits stem cell-like properties in melanocytes
The depigmentation potential of MSX1 in melanocytes led us to hypothesize that
MSX1 may dedifferentiate epidermal melanocytes towards a precursor cell-like state.
When cultured under melanocyte-specific conditions (254CF media), we observed
that MSX1-cells had a tendency to cluster together and form spheres, a classical
growth pattern of neural precursor cells in vitro 39,51 (Figure 3.6, upper left panel,
white arrows). These spheres are morphologically similar to dermis-derived NCLSC
spheres and to Notch1-reprogrammed melanocytes (Figure 3.6, middle left panel).
After 2 weeks of exposure to StemPror, MSX1-melanocytes formed tight round
spheres, whereas GFP-transduced control cells died off in necrotic clusters (Figure
3.6, right panels). Notch1-reprogrammed melanocytes with a high sphere-forming
capacity were used as a positive control.
Notably, MSX1-spheres expressed high levels of p75 (nerve growth factor receptor,
CD271), a well-reported neural crest marker, at levels similar to NCLSCs (Figure
3.7). The expression of p75 was not restricted to MSX1-spheres, as MSX1-expressing
melanocytes that were grown as an adherent layer displayed intermediate levels of p75
as well (Figure 5.1). These data suggested that MSX1-cells up-regulated expression
of the neural crest marker p75 under hESC conditions regardless of sphere formation.
We presumed that MSX1 rendered the cells more adaptable to hESC conditions,
as control melanocytes were not able to survive in these stem cell-selective conditions.
Therefore, we evaluated cell death in StemProrusing a low-attachment surface (Fig-
ure 3.8). After 7 days, we observed that control cells formed irregular unspecific
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Figure 3.6: Brightfield microscopy revealing increased clustering and formation of
spheres when cells are cultured as an adherent monolayer (left panel). White ar-
rows highlight areas of increased cellular density resembling spheres. Sphere for-
mation is more evident under stem cell-specific conditions (StemPror). MSX1-
transduced melanocytes form tight spheres even after prolonged exposure (2-3
weeks) to StemPror in low attachment plates (right panel). No spheres could
be detected in GFP-expressing control melanocytes (GFP) under either condi-
tion. Notch1-transduced melanocytes with prominent sphere formation served
as a positive control. Scale bars: 200 µm
Figure 3.7: Immunofluorescent staining reveals high expression of p75 in MSX1-
spheres. Dermal spheres with high levels of p75 served as positive control. Note
that control cells did not form tight spheres. Scale bars: 100 µm
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cell clusters while MSX1-spheres appeared round and regular in form and size. The
necrotic clusters that formed from control cells broke apart over time, and were al-
most all dead within 3 weeks. In contrast, MSX1-cells formed tight spheres with little
cell death.
Figure 3.8: Cells were cultured in low attachment plates for up to 3 weeks and
were stained with ethidium-homodimer1 (EthD-1) at days 7, 14, and 21. Pos-
itive staining (red fluorescence) indicates cell death. After 21 days, MSX1-
infected melanocytes still formed tight spheres with only a few dead cells within
the cores of the spheres compared to control cells. Scale bars: 200 µm
Our observation that ectopic MSX1 enables mature melanocytes to survive and
form p75-expressing spheres under hESC conditions implied that MSX1-melanocytes
are similar to neural crest-derived progenitor cells. We therefore investigated whether
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MSX1-melanocytes could give rise to mesenchymal and/or neuronal cell types. MSX1-
melanocytes began to express lineage-specific markers and underwent characteristic
morphologic changes when subjected various to differentiation media. When MSX1-
melanocytes were trans-differentiated to smooth muscle cells, they presented smooth
muscle actin filaments in their abundant cytoplasm (Figure 3.9, upper panels). Upon
neuronal differentiation, neurofilament-L was predominantly expressed in the perin-
uclear cytoplasm, an area that corresponds to axon hillocks in neurons. Some cells
developed a very long and subtle dendrite resembling an entire axon (Figure 3.9,
middle panels, white arrow and white dotted line, respectively). Adipogenesis was
confirmed by oil-red-O-staining (Figure 3.9, lower panels). Approximately 1% of the
cells exhibited these distinctive changes, indicating that this differentiation process is
not very efficient.
Figure 3.9: When exposed to differentiating media conditions, MSX1-infected
cells express markers of smooth muscle cell-, neural cell-, and adipocyte-
differentiation. After 2 weeks, immunofluorescent staining shows the expression
of smooth muscle actin (SMA, upper panel) and neurofilament-L (NF-L, middle
panel). Upon neural differentiation, cells acquired a shape resembling neural
cells with an axon hillock (white arrow) and a subtle axon-like structure (white
dotted line). Lipid droplets were detected by Oil-red-O-staining (lower panel);
DAPI = 4,6-diamidino-2-phenylindole. Scale bars: 100 µm
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3.3 MSX1 is a transcriptional repressor of M-MITF in the melanocytic
lineage
Figure 3.10: MSX1 was induced as early as 3 h after induction and increased
progressively at later time points. MSX1 levels were very low when cells were
not stimulated (0h), excluding any basal leakage of the Tet-ON system. Blotting
for β-actin and lamin A/C serve as a loading control for whole cell (left panel)
and nuclear fraction (right panel) proteins, respectively.
We next explored potential downstream mediators of MSX1 that are involved
in this overt dedifferentiation phenotype. To identify immediate targets of MSX1,
we generated a tetracycline-inducible system (Tet-ON) in order to express MSX1 in
primary melanocytes (MSX1-pLUTpoly, iMSX1) in a clean and rapid way starting
at defined time points. As early as 3 h after treatment with 500 ng/ml doxycy-
cline, MSX1 protein was detectable in the cytoplasm, and its expression was further
increased at later time points (Figure 3.10, left panel). As a transcription factor,
MSX1 functions mainly inside the nucleus, and we therefore measured protein levels
of MSX1 isolated from the nuclear fraction of melanocytes (Figure 3.10, right panel).
Exogenous MSX1 was present in nuclei as early as 3 h after induction, yet at lower
levels compared to the cytoplasm. Altogether, this Tet-ON system enabled us to
generate MSX1 translocated to the nucleus in a rapid and non-leaky manner. There-
fore, we supposed that immediate target genes would be affected shortly after the
induction of MSX1.
In an unbiased approach to screen for direct targets of MSX1, we performed
a microarray-based global gene expression analysis in iMSX1-expressing cells be-
fore (0 h) and after induction (6 h). From the analysis of two different cultures
of melanocytes, we identified 210 genes that were significantly up-regulated and 283
genes that were significantly down-regulated. Strikingly, MITF was found among the
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Figure 3.11: qRT-PCR confirming the down-regulation of M-MITF in foreskin-
derived melanocytes 6 h after induction of MSX1. Cells infected with either
an empty vector (pLUTpoly) or inducible MSX1 (iMSX1) were exposed to
500 ng/ml doxycycline (+Dox) or PBS (-Dox). MSX1 was rapidly induced in
iMSX1-cells upon treatment (left panel). Correspondingly, M-MITF decreased
to 50% of its initial level, whereas it appeared unaltered in control cells, i.e.
pLUTpoly +/- Dox and iMSX1 -Dox (right panel). *p<0.001, **p<0.0001.
most down-regulated genes, suggesting a direct transcriptional regulation by MSX1.
We validated the microarray results by qRT-PCR, revealing a decrease in levels of
M-MITF to approximately 50% of basal levels after 6 h, suggesting that M-MITF
is directly repressed by MSX1 at the mRNA level (Figure 3.11). Within 60 h of the
induction of MSX1, M-MITF was decreased significantly at the protein level in a
dose-dependent manner, while E-Cadherin and NCAM, both of which were found to
be altered in cells with stable expression of MSX1, remained unaltered at this early
time point (Figure 3.12). We measured levels of mature spliced mRNA versus nascent
unspliced mRNA52 over 24 h to investigate whether the decrease in M-MITF mRNA
is due to the decreased stability of its mRNA or a reduced de novo transcription rate.
The data from qRT-PCR revealed an induced inverse correlation of MSX1 expression
and a reduction of both spliced and unspliced M-MITF (3.13). M-MITF was down-
regulated as early as 6 h and progressively diminished with a negative peak at 24 h,
suggesting that de novo transcription of M-MITF was impaired.
In contrast, known target genes of MSX1 involved in neural crest development,
such as SLUG, SNAIL and FOXD3 44, all remained unaltered in human melanocytes
(Figure 5.2a). Levels of SNAIL and SLUG remained relatively constant over 24 h
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Figure 3.12: MSX1 was gradually expressed with increasing concentrations of
doxycycline (0-1000 ng/ml). After 60 h, levels of M-MITF, NCAM and E-
cadherin were assessed in melanocytes. E-cadherin and NCAM, both of which
were found to be altered in cells with stable expression of MSX1, remained unal-
tered at the early time point. In contrast, M-MITF was diminished, suggesting
a specific direct and rapid transcriptional regulation by MSX1.
Figure 3.13: An inverse correlation between MSX1-induction and M-MITF ex-
pression over 24 h. M-MITF levels were measured with two different sets
of primers distinguishing between newly transcribed (unspliced) and mature
(spliced) RNA; *p=0.0125, **p<0.001.
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induction of MSX1in human melanoma WM35 cells, as well as levels of WNT5A,
which harbors several MSX1-binding sites in its proximal promoter area53 (Figure
5.2b).
Figure 3.14: Immunoblot revealing MSX1 induction as early as 3 h in WM88
melanoma cells. Endogenous levels of MSX1 were very low when cells were not
stimulated. Blotting for β-actin serves as a loading control.
The robust down-regulation of M-MITF in MSX1-expressing melanocytes suggests
that M-MITF is a potential candidate as a direct target of MSX1. We assessed the
transcriptional activity of the M-MITF promoter in iMSX1-infected WM88 cells using
luciferase-reporter constructs (Figure 3.15). MSX1-mediated suppression of the M-
MITF promoter was observed with the constructs hMIP-2kb, -1kb and -0.5kb, which
harbor the proximal 2kb, 1kb, and 0.5kb of the M-MITF promoter, respectively. This
indicated that MSX1 consensus binding sites exist within nucleotides -514 to +121
relative to the M-MITF transcription start site (Figure 3.15).
To determine whether M-MITF is a direct transcriptional target of MSX1, we
analyzed the sequence of the M-MITF promoter using the TRANSFACr54. Two
putative MSX1-binding sequences with the consensus motif TAATT55,56 were predicted
within the region (-56 and +53) (Figure 3.16).
To test whether MSX1 binds directly to the M-MITF promoter, we performed
chromatin immunoprecipitation (ChIP) assays with WM35 cells transfected with the
pCS2-3XFLAG-MSX1 construct (Figure 3.17), a 3X FLAG-tagged MSX1 under a
constitutive promoter. ChIP assays showed that exogenous MSX1 was strongly bound
to both the sequences at the +53 and -56 sites of the M-MITF promoter region
compared to the control region from a gene desert on human chromosome 12 (Figure
3.18). Together, these data demonstrated that MSX1 directly interacts with the
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Figure 3.15: Luciferase reporter assay demonstrates that MSX1 regulates M-
MITF transcriptional activity. iMSX1-infected WM88 cells co-transfected with
hMIP-2kb, -1kb or -0.5kb show a decrease in luciferase activity upon induction
with 500 ng/ml of doxycycline compared to control cells treated with PBS. The
repressive effect is still seen with the most truncated version of the reporter
construct, hMIP-0.5kb, indicating that a consensus site exists close to the TSS.
Figure 3.16: Schematic representation of the proximal 500 base pairs of the M-
MITF promoter. Predicted MSX1 consensus sites are at +53 and -56, while
a PAX3 binding site exists at -268, and three SOX10 binding sites exist at
positions -243, -283, and -303.
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M-MITF promoter as a transcriptional repressor.
Figure 3.17: Immunoblot analysis revealing the expression of FLAG-tagged
MSX1 protein transduced in WM35 melanoma cells (fMSX1). The band size
of FLAG-tagged MSX1 is a few kDa larger compared to the size of non-tagged
MSX1 WM35 cells (iMSX). Blotting for β-actin serves as a loading control.
Figure 3.18: ChIP assays showing FLAG-MSX1 enrichment (fMSX1)at the pre-
dicted binding sites compared to the control region from a gene desert on human
chromosome 12.
3.4 Expression of MSX1 is sufficient and necessary for the migration of
melanoma cells in vitro
An important hallmark of neural crest cells is their ability to migrate to dis-
tant sites throughout the embryo. To address whether MSX1 regulates cell migra-
tion, we subjected (stably infected) MSX1-melanocytes to Boyden Chamber assays.
The migratory potential of MSX1-melanocytes was significantly higher compared to
melanocytes infected with the control pLU-EF1aL-IRES-BLAST virus (Figure 3.19).
Similarly, gain of function-experiments in two melanoma cell lines exhibiting low
intrinsic levels of MSX1 were performed: the radial growth phase (RGP)-like WM35
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Figure 3.19: Boyden Chamber assays revealing the migratory ability of MSX1
expressing melanocytes. Cells migrated along a chemical gradient of growth
supplement. After 18 h, membranes were fixed and stained with DAPI. Assays
were quantified by counting 5 high power fields (HPF) per membrane randomly
taken at a magnification of 200X (left panel); MSX1-infected cells exhibited an
increased migratory potential compared to control cells (right panel). Data are
means ± s.d. with n=3. Scale bars: 200 µm *p<0.0001.
(Figure 3.20) and metastasis-derived WM3451 cell (Figure 3.21). While control cells
displayed a bipolar spindle-shape, MSX1-WM3451 cells were polygonic and flattened
(Figure 5.3a). In WM35 cells, the effects of MSX1 were not evident when cells were
cultured in Mel2% (Figure 5.3b, left panels); however, upon exposure to hESC media
(StemPror), control cells formed big clusters, the typical growth pattern of WM35
cells, whereas MSX1-WM35 cells were finely dispersed and grew in multiple small
colonies (Figure 5.3b, right panels).
When subjected to Boyden Chamber assays, MSX1 increased the migration of
WM35 cells, a cell line that has little migratory and invasive potential per se (Figure
5.4). In metastatic WM3451 cells, the expression of MSX1 led to a 7-fold increase
in migration (Figure 3.21). Importantly, ectopic MSX1 did not alter cell growth and
proliferation (Figure 5.3), indicating that it specifically promotes cell migration.
Furthermore, we performed loss of function-experiments in melanoma cells using
lentiviruses encoding shRNAs specific to MSX1. MSX1 antibodies usually detect two
MSX1-specific bands in immunoblots, most probably caused by different sumoylation
patterns at lysine residues (K15 and K133) of the MSX1-protein57. RNAi affected
both bands in 451Lu cells, with a stronger knockdown of the lower band (Figure 3.22,
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Figure 3.20: Left: Immunoblot showing stable ectopic expression of MSX1 by
lentiviral vector pLU-EF1aL-MSX1-IRES-BLAST in WM35 melanoma cells,
which have low endogenous levels of MSX1. Parental uninfected cells served
as an additional control and showed similar endogenous levels as control cells
infected with the empty vector virus. Blotting of β-actin served as a loading
control. Right: WM35 cells subjected to Boyden Chamber assays as cells mi-
grated along a chemical gradient of serum and insulin for 6 h prior to fixation
and staining with DAPI. MSX1-infected cells were highly migratory compared
to control cells; *p=0.0266. Data are means ± s.d. with n=3. Scale bars: 200
µm
Figure 3.21: Right: Immunoblot showing stable ectopic expression of MSX1 by
lentiviral vector pLU-EF1aL-MSX1-IRES-BLAST in WM3451 melanoma cells,
which have low endogenous levels of MSX1. Parental uninfected cells served
as an additional control and showed similar endogenous levels as control cells
infected with the empty vector virus. Blotting of β-actin served as a loading
control. Right: WM3451 cells subjected to Boyden Chamber assays as cells
migrated along a chemical gradient of serum and insulin for 6 h prior to fixation
and staining with DAPI. MSX1-infected cells were highly migratory compared
to control cells; p=0.0216 for WM3451
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top left panel). Furthermore, qRT-PCR analysis validated a solid down-regulation
(>50%) of MSX1 with two shRNA sequences (sh MSX1 3 and sh MSX1 5) (Figure
5.5). We subjected these knock-downs to Boyden Chamber assays to characterize
their effects on cell migration. Silencing of endogenous MSX1 impaired cell migration
in both clones compared to control vector-infected cells (Figure 3.22, right). Together
with the gain of function-experiments reported above, these data indicate that MSX1
is both sufficient and necessary to promote the migration of melanoma cells in vitro.
Figure 3.22: Left: Immunoblot revealing stable knock-down of MSX1 in 451Lu
cells, a melanoma cell line with high endogenous levels of MSX1. Cells were in-
fected with lentiviral shRNAs targeting 4 different sites of the MSX1 gene (sh -
MSX1 1, 3, 4, 5). Parental uninfected and empty vector-infected cells showed
high levels of MSX1. Significant down-regulation (>50%) was achieved after
infection with sh MSX1 3 and sh MSX1 5. Levels of β-actin indicate even load-
ing. Right: Cells infected with control vector virus, sh MSX1 3, and sh MSX1 5
were tested in Boyden Chamber assays, stained and quantified after 6 h. The
migratory potential of 451Lu cells was attenuated in cells infected with both
sh MSX1 3 and sh MSX1 5 compared to control cells. Assays were quantified
by counting 5 high power fields (HPF) per membrane randomly taken at a mag-
nification of 40X; *p=0.0295 for sh MSX1 3, p=0.0363 for sh MSX1 5. Data
are means ± s.d. with n=3. Scale bars: 500 µm
3.5 Expression of MSX1 correlates with disease progression in melanoma
Our data demonstrated that MSX1 reprograms melanocytes into a neural crest-
like state, and has a significant impact on migration in the melanocytic lineage.
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We therefore hypothesized that MSX1 is re-activated in melanoma and contributes
to the disease progression. Notably, expression of MSX1 was up-regulated in most
melanoma cell lines tested compared to normal melanocytes (Figure 3.23). WM35
(RGP), WM115 (vertical growth phase: VGP) and WM858 (metastatic phase) cells
displayed lower endogenous levels of MSX1 compared to 451Lu (metastatic phase)
and WM1366 (VGP) cells, which exhibited strong MSX1 expression.
Figure 3.23: Immunoblot analysis assessing endogenous levels of MSX1 in
foreskin-derived melanocytes (FOM-) and a panel of melanoma cells (WM-).
Most melanoma cell lines express MSX1, yet normal melanocytes barely ex-
press MSX1. The detection of MSX1 consistently revealed two bands which
might be caused by different patterns of sumoylation. Blotting of β-actin indi-
cates even loading.
This small panel of melanoma cell lines did not provide enough statistical power
to draw a correlation between total levels of MSX1 and disease progression, so we
used the publicly available dataset GSE1239158 to analyze the relationship between
the expression of MSX1 and the clinical stage of melanoma. This dataset consists
of 58 nevi samples, 16 RGP melanoma samples, 30 VGP melanoma samples, and 10
melanoma metastasis samples. Within this cohort, expression of MSX1 was signifi-
cantly correlated with disease progression (p=5.15x10-6) (Figure 3.23c).
Furthermore, out of 7 primary melanomas, 3 showed strong positivity for MSX1
staining (Figure 3.24). MSX1 expression was specifically localized in melanoma cells
33
and not in adjacent stromal cells or in keratinocytes, suggesting that up-regulation
of MSX1 in the advanced stages occurs specifically in melanoma cells. Both nodular
melanoma and superficial spreading melanoma tissues expressed MSX1 regardless of
their differences in histological type.
Figure 3.24: Immunohistochemical analysis revealed the expression of MSX1 in
patient-derived melanoma specimens. Three samples with positive staining are
shown (Melanoma 1-3). The tumor mass of melanoma 1 displayed robust cy-
toplasmic staining in contrast to surrounding connective and fat tissues. Also,
single pleomorphic melanoma not connected to the tumor bulk cells showed pos-
itive staining (melanoma 1, black arrows). Note that nests of melanoma cells
located within the epidermis exhibited strong expression of MSX1 compared to
the adjacent epidermis (melanoma 2 and 3, black arrows).
3.6 MSX1 promotes tumor growth and metastasis in vivo
We next wished to observe the activity of MSX1 in vivo in a mouse setting.
451Lu cells expressing lentiviruses encoding either sh MSX1 3 or the control vec-
tor pLKO.1 were sub-cutaneously injected into immunodefficient NOD.Cg-Prkdcscid
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Il2rgtm1Wjl/SzJ JAX R© (NOD scid gamma (NSG)) mice (1x105 cells / mouse). Tumor
growth was measured every 3 to 4 days for up to 34 days post-injection before the
mice were sacrificed. While the tumors from the control virus (pLKO.1) continued
to grow at a normal logarithmic rate, the tumors from the MSX1-knock-down mice
had severely impaired growth (Figure 3.25). Furthermore, the tumor was not palpa-
ble and barely detectable until the mice were euthanized and dissected. These data
demonstrate that knock-down of MSX1 hindered in vivo proliferation of melanoma
cells, which was unaffected in vitro.
Figure 3.25: 451Lu MSX1-knock-down cells were sub-cutaneously injected into
NSG mice and tumor growth was measured. Tumors from the control cells
grew normally while tumor growth from the knock-down cells was attenuated.
We also performed intravenous tail-vein injections with 451Lu MSX1-knock-down
cells (1x105 cells / mouse) as a preliminary metastasis/colonization model. Out of 5
control mice injected, 4 mice developed severe liver metastases (Figure 3.26), while
only 1 out of 5 mice with MSX1-knock-down cells developed liver metastases. The
control cells were able to colonize the liver niche much better than the MSX1-knock-
down cells, indicating that MSX1 is crucial for extravasation and colonization, but
not intravasation.
While these animal experiments are very preliminary (sub-cutaneous: 2 control
and 3 knock-down; tail-vein: 5 mice per group), they indicate to us that MSX1 plays
a crucial role in tumor development in vivo. Taken together, these data suggest that
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Figure 3.26: Representative liver samples from mice with 451Lu MSX1-knock-
down cells intravenously tail-vein injected. Four out of five control mice devel-
oped severe liver metastases.
MSX1 is required by the metastasis program to fully complete.
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CHAPTER 4: DISCUSSION
In this study, we investigated the function of MSX1 in the melanocytic lineage.
Both in melanocytes and in melanoma cells, the expression of MSX1 decreased pig-
mentation and the expression of melanocytic markers, and the cells behaved in a man-
ner similar to a neural crest precursor-like population. Mechanistically, we identified
MSX1 as a novel transcriptional repressor of M-MITF in the melanocytic lineage.
In agreement with previous studies (reference), a global unbiased screen for target
genes showed that MSX1 could activate or repress various targets in melanocytic
cells. While the reduction of M-MITF upon MSX1-induction may contribute signifi-
cantly to the dedifferentiation of melanocytes, more efforts are warranted to elucidate
whether other genes are involved in the phenotypic changes we observed.
4.1 MSX1 cofactors and target genes
Often, transcription factors work in tandem with other cofactors, and their func-
tion may vary depending on which factors are present. MSX1 has been shown to
recruit the Polycomb Repressive Complex 259 in mouse cells, and more specifically
the EZH2 subunit. This transcriptional machinery has histone methyltransferase ac-
tivity and trimethylates histone H3 on lysine 2760. SOX10 has been a known activator
of MITF along with other factors such as paired-box homeodomain transcription fac-
tor PAX361. Interestingly, a recent report has shown opposing roles for PAX3 and
MITF62.
Whether a repressor or activator turns on or off a gene is very heavily context
dependent. The choice of an appropriate cofactor will influence the results of deter-
mining the transcriptional network of MSX1, at a specific melanoma stage. Ongoing
work is being done on isolating partner cofactors of MSX1, which will then be followed
by ChIP-seq. Binding motif analysis can be performed, separating the gene list into
genes directly bound by MSX1 or genes where MSX1 indirectly affects.
We observed increased migration after ectopic expression of MSX1, but the molec-
ular mechanisms have not been disseminated. While MITF may play a major role,
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MSX1 may increase invasion in a MITF-independent manner through eliciting EMT
genes. Alternatively, we are also interested in whether a cell that has already become
invasive and already expressing EMT markers is able to produce a change in MSX1.
Although this would imply that MSX1 is not a master regulator for metastasis in
melanoma, this could identify factors that can increase expression of MSX1, while
MSX1 is still required for further events in invasion.
4.2 Phenotypic plasticity of melanocytic cells
M-MITF is expressed early in the lineage commitment of melanocytic cells from
the neural crest29. Hence, the repression of M-MITF by MSX1 could play a key
role in preventing neural crest stem cells from a premature melanocytic fate restric-
tion. In the neural crest, MSX1 acts upstream of EMT transcription factors FOXD3,
SNAIL, and SLUG44. FOXD3 expression in the avian embryo has been shown to
indirectly repress MITF through interaction with PAX363. Moreover, FOXD3 and
MITF expression are mutually exclusive. Our data suggests that MSX1 acts in a
FOXD3-independent manner in melanocytes; however, it remains to be determined
whether FOXD3 is a downstream target of MSX1 in melanoma cells.
MITF expression in melanoma is complex. Varying levels of M-MITF in melanoma
results in a variety of contrasting phenotypes; low levels of M-MITF are correlated
with a stem-like phenotype of slow proliferating cells with a high invasive potential.
Moderate M-MITF levels are correlated with a proliferative phenotype, while high
levels of M-MITF result in a growth-arrested, yet differentiated phenotype64. This
has been proposed in the “MITF rheostat model” as MITF expression correlates
with phenotypic switching in melanoma cells. Metastatic melanoma cells can switch
between invasive or proliferative gene signatures65. The many transcriptional and
post-translational methods with which MITF can be modified allow for numerous
proteins to interact and affect the cell. Our data has shown one way in which MITF
can be repressed by MSX1.
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4.3 Signaling from the tumor microenvironment
Conversely, we are also interested in upstream factors that can affect the expres-
sion levels of MSX1. The potential for tumor cells to increase MSX1 expression
in response to local paracrine factors has major implications for therapeutic strate-
gies. During embryonic development, a concerted effort of Wnt and BMP signaling
pathways promote neural crest formation and the specification of neural crest cells,
increasing expression of MSX131 66 30 44. These are also factors that are secreted by
the tumor microenvironment, along with pro-inflammatory chemo- and cytokines67.
Preliminary data shows that IL8 can increase MSX1 transcript levels in melanocytes
(Figure 5.6), while BMP4 increases MSX1 expression in WM3451 melanoma cells
(Figure 5.6). This idea supports the dynamic stemness model, as neighboring cells
can secrete factors that dedifferentiate target cells through an increase in MSX1 levels.
These questions serve to narrow down when MSX1 is the most crucial during
melanoma progression (i.e., Is MSX1 a master regulator of switching the cells to an
invasive phenotype, or is MSX1 a result of an invasive phenotype). An early response
has clinical relevance as it can serve as a prognostic marker. While a transcrip-
tion factor has poor value for targeted therapeutics, it has the ability to influence
more accessible downstream targets, such as kinase signaling proteins or cell-surface
molecules.
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CHAPTER 5: APPENDIX A
Table 5.1: Primer sequences used for qRT-PCR
Gene Forward Reverse
GAPDH ATGGAAATCCCATCACCATCTT CGCCCCACTTGATTTTGG
MSX1 CTCCGCAAACACAAGACGAAC CACATGGGCCGTGTAGAGTC
MITF spliced TCAGGTGCAGACCCACCTCGAA GGCACCGGTGGCATGACATGAT
MITF unspliced AAGAGACGTATAGTTAATTAGCAG GGCTCTTCCTTCAGGCACAAACAT
Tyrosinase CTGGAAGGATTTGCTAGTCCAC CCTGTACCTGGGACATTGTTC
Table 5.2: Primer sequences used for ChIP
Gene Forward Reverse
MITF 1 ACCTTCTCTTTGCCAGTCCATCTT TGGCACCAATCCAGTGAGAGAC
MITF 2 AGACCAAACTCGTAGGGCTTCCA TTTATCACAGAAGCCCTGCTTATAATAAC
Negative control ATGGTTGCCACTGGGGATCT TGCCAAAGCCTAGGGGAAGA
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Figure 5.1: Immunofluorescence (IF, middle panel) revealing the expression of
p75 in MSX1-expressing foreskin- derived melanocytes that were cultured as
adherent cells under stem cell conditions (StemPro R©). Upon prolonged expo-
sure to StemPro R©(i.e. >3 weeks), MSX1-cells lost most of their dendrites and
acquired a melanobastic shape. In contrast, single necrotic cells were detected
in an empty vector-infected control population. Note the slight cytoplasmic pos-
itivity for p75 in MSX1-transduced melanocytes (green fluorescence, arrows).
Staining for p75 in adherent cells was much weaker compared to spheres that
were generated in StemPro R©under low attachment conditions (Figure 3.7), sug-
gesting that the formation of spheres is conducive to p75-expression. In both
cases, the same primary antibody was applied. Scale bars: 100 µm.
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Figure 5.2: (a) qRT-PCR analysis measuring the expression of SNAIL, SLUG,
and FOXD3 after induction of MSX1 in foreskin-derived melanocytes. All 3
transcription factors are known downstream mediators of MSX1 in the for-
mation and specification of the neural crest. mRNA levels remained largely
unaltered upon forced ectopic expression of MSX1. Levels were measured at
several time points after doxycycline was added at a concentration of 500 ng/ml.
(b) qRT-PCR measuring SNAIL, SLUG, and WNT5A after the induction of
MSX1 in WM35 cells. None of these reported targets displayed major changes
at the gene level after MSX1 was switched on by doxycycline (500 ng/ml).
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Figure 5.3: (a) Empty vector-infected WM3451 cells (upper panel) displaying a
bipolar spindle-shape reminiscent of melanocytes. Upon stable expression of
MSX1 (lower panel), cells acquired a mesenchymal fibroblastoid morphology
and were more scattered. Some spots on the culture dish showed two distinct
populations: bipolar cells resembling parental WM3451 cells (solid arrow) and
small polygonic and dispersed cells with loosened cell-cell contacts (dotted ar-
rows); cells were cultured in Mel2%. (b) In WM35 cells, MSX1-expressing
cells (right upper panel) appeared smaller, less dendritic and more packed than
parental cells (left upper panel) when cultured in Mel2%. Shortly after the
media was switched from Mel2% to StemPro R©, control cells began to grow in
big clusters with a sphere-like formation (left lower panel). In contrast, MSX1-
expressing cells formed smaller clusters and grew out as single cells as indicated
by single cells attached to the culture dish (right lower panel). All images were
taken with a Nikon Inverted microscope (Nikon Instruments). Scale bars: 200
µm.
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Figure 5.4: Ectopic expression of MSX1 did not alter the proliferation of foreskin-
derived melanocytes (FOM). Once a pure population of MSX1-expressing
melanocytes was obtained after selection, cell growth was assessed by cell count-
ing (left panel) and MTS assays (right panel). Control cells (infected with empty
vector) were compared to cells that stably expressed MSX1. Equal values at
d1 showed that cells were seeded at the same density. (b) Effects of MSX1 on
the proliferation in WM3451 and WM35 cells. Both cell lines exhibited low
endogenous levels of MSX1. Cells stably infected with MSX1 (MSX1) were
compared to empty vector-infected cells (control). Cell growth was assessed by
cell counting (left panels) and MTS assays (right panels). In WM3451 cells,
MSX1 did not have any effects on proliferation. In WM35 cells, there was a
slight increase in the proliferation of MSX1-expressing cells.
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Figure 5.5: qRT-PCR assessing the shRNA- mediated knockdown of MSX1
in 451Lu cells. Consistent with the data from whole cell proteins (Figure
3.10), best results were achieved with sh MSX1 3 and sh MSX1 5. Cells trans-
fected with sh MSX1 3 and 5 were used subsequently for migration assays.
*p<0.0001.
Figure 5.6: Left: qRT-PCR assessing the effects of IL8 in increasing concentra-
tions in melanocytes over 24 h. Endogenous MSX1 fold change is positively
correlated with IL8 dosage. Right: qRT-PCR assess the effects of growth fac-
tors TGFβ, BMP4, FGF, IL6, and IL8 at 10ng/ml in WM3451 melanoma cells
over 24 h. These factors are secreted by the tumor microenvironment. BMP4
is able to elicit a five-fold increase in endogenous MSX1 expression.
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CHAPTER 6: METHODS
Cell culture
Human melanoma cell lines were isolated and cultured in Mel2% medium as
previously described15. Human primary melanocytes were isolated from the epi-
dermis of neonatal foreskins and were maintained in 254CF media (Life Technolo-
gies). NCLSCs were isolated from the dermis of human neonatal foreskins as de-
scribed elsewhere41 and were cultured as spheres in human embryonic stem cell cul-
ture medium (StemPro R© hESC SFM, Life Technologies) without bFGF. Intracel-
lular Notch1 (NIC)-expressing and green fluorescent protein (GFP)-expressing con-
trol melanocytes were generated as described38. HEK293T cells used for producing
lentiviral particles were cultured in DMEM (Life Technologies) supplemented with
10% FBS.
Cell viability assays
For cell counts, 8x103 WM35 cells, 2x104 WM3451 cells, or 5x104 melanocytes
were seeded per well in 6-well plates. Cells were cultured as an adherent monolayer
for up to 8 days without adding new media. At days 1, 4, and 8, cells were harvested
using 0.05% trypsin diluted in versene (Life Technologies) and were counted in a
conventional hemocytometer. For MTS assays, cells were seeded with 8x102 (WM35
and WM3451 cells) or 2x103 (melanocytes) cells per well in 96-well plates. At days 1,
4, and 8, CellTiter 96 R© AQueous MTS reagent (Promega) was added at 4 mg/ml to
each well and cells were incubated for 4 h at 37◦C. Absorbance was measured using
an EL800 Microplate Reader (Bio Tek) at 490 nm.
Boyden chamber migration assays
Assays were performed using semi-permeable, uncoated Transwell R© membranes
with a pore size of 8.0 µm in a 24-well plate format (Corning). 5x104 cells were
seeded in the upper chamber of the Transwell R©. Melanoma cells and foreskin-
derived melanocytes were allowed to migrate along a chemical gradient of FBS or
human melanocyte growth supplement 2 (HMGS-2; Life Technologies), respectively.
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The membranes were fixed in 4% paraformaldehyde and stained with 4’,6-diamidino-
2-phenylindole (DAPI, Vector Labs) at time points as specifically indicated. Cell
numbers from random fields were counted using a Nikon E600 upright microscope
(Nikon Instruments) at 200X (melanocytes, WM35, and WM3451 cells) and at 40X
(451Lu cells).
Plasmid construction
Human MSX1 cDNA (Clone ID: 4893288) was purchased from OpenBiosystems
(Thermo Fisher). For stable expression, MSX1 was digested with BamHI and XhoI
and cloned into the lentiviral construct pLU-EF1aL-IRES-BLAST using the BamHI
and SalI sites to generate pLU-EF1aL-MSX1-IRES-BLAST (cloning site destroyed
by compatible ends). For inducible expression, MSX1 was cloned into pLUT-poly
(tetracycline-sensitive CMV promoter) using the NheI and EcoRI sites to generate
pLUT-poly-MSX1. For FLAG-tagged expression, pCS2-3XFLAG-MSX1 generated
by sub-cloning the open reading frames of MSX1 into pCS2-3XFLAG, a modified
pCS2-Flag vector (Addgene, 16331).
Lentiviral constructs encoding shRNA sequences targeting MSX1 were purchased
from OpenBiosystems (Oligo IDs: TRCN20414-20418; referred to as sh MSX1 1-5).
The backbone construct (pLKO.1) served as internal control.
The constructs pGL3-hMIP-2kb and -1kb bearing the nucleotides -2018 and -1014
to +121 relative to the human M-MITF transcription start site (TSS), respectively,
have been previously described52. The construct pGL3-hMIP-0.5kb harboring the nu-
cleotides -514 to +121 relative to the TSS was generated by amplification of the pro-
moter of the human M-MITF gene. PCR was performed using the primers 5’-ATT AGG
TAC CTA TGT AGC TAA GAA TAA GGT G-3’ (forward, with an added KpnI-site) and 5’-
ATT ACC ATG GCC AGC ATA ACA ATG TTT TAG-3’ (reverse, with an added NcoI-site).
The resulting amplicon was purified, double-digested with KpnI and NcoI, and cloned
into pGL3-basic vector (Promega).
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Lentivirus production
Lentiviral particles were produced by seeding 3.8 x 105 human embryonic kidney
293T cells into 10 cm plates, grown in DMEM supplemented with 10% FBS. The cells
were co-transfected with second generation packaging (psPAX2, 9 µg) and envelope
(pMD2.G, 0.9 µg) plasmids along with the corresponding lentiviral vector (9 µg).
The next morning, the media was replaced with high-serum growth medium (30%
FBS in DMAM). Viral supernatants were harvested 48 h and 72 h post-transfection,
pooled together, and aliquots were stored in -80◦C. Cells were infected overnight with
the viral supernatant diluted 1:1 with culture medium in the presence of 6 µg/ml
polybrene. Following infection, the cells were either kept under blasticidin selection
(6-10 µg/ml) or selected with puromycin (1.5-2 µg/ml) for 3 days.
Viability staining
Cells were seeded in low-attachment 12-well plates (Corning) in StemPro R©medium
(Life Technologies). After 7, 14, and 21 days, cell death was assessed with the red
cell-impermeant viability indicator Ethidium-Homodimer1 (EthD-1) (Life Technolo-
gies). EthD-1 was diluted at 4 µM in ice-cold PBS and was directly added to cells
at a 1:10 dilution with media. Cells were incubated for 30 min in the dark at room
temperature. Dead cells, marked by bright red to orange fluorescence, were observed
using a Nikon E600 upright microscope (Nikon Instruments).
Quantitative real-time PCR (qRT-PCR)
Total mRNAs were collected from cells using an RNeasy kit (Qiagen). Cells were
washed twice in PBS to remove traces of media, and then were lysed and harvested
with a sterile cell scraper. Lysates were homogenized with QIAshredder R© microcen-
trifuge spin-columns (Qiagen) prior to purification. RNAs were reverse transcribed
into cDNAs with a SuperScript III RT kit (Life Technologies) according to the man-
ufacturers instructions. Quantitative real-time PCR was performed using the Power
SYBR Green PCR Master Mix-kit (Applied Biosystems) on an ABI 7500 Fast Real-
Time PRISM machine. Values obtained were normalized to levels of glyceraldehyde
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3-phosphate dehydrogenase (GAPDH ). Sequences of the primers used are listed in
Table 5.1.
Immunoblotting
Cells were washed two times in 1X PBS and lysed in RIPA buffer for 15 min
on ice to generate whole cell lysates. Nuclear fraction proteins were isolated using
a Nuclear Extract Kit (Active Motif) according to the manufacturers instructions.
Protein concentration was determined using the Bio-Rad Protein Assay Kit II (Bio-
Rad, 500-0002) using a bovine serum albumin standard curve. 10-30 µg of protein
were separated on acrylamide gels (8% or 10%) and were then blotted on nitrocellu-
lose membranes (Bio-Rad, 170-4159) using a Trans-Blot R© TurboTM instrument (Bio-
Rad, 170-4155). Membranes were blocked with OdysseyTM Blocking Buffer (LI-COR,
927-40000) for 1 h at room temperature with rocking. Membranes were hybridized
overnight with primary antibodies for MSX1 (Cell Signaling, 4787S, 1:750), M-MITF
(clone C5, Abcam, ab12039, 1:500), NCAM-L1 (Santa Cruz Biotechnology, sc-374046,
1:1000), E-cadherin (Life Technologies, 13-1700, 1:1000), or β-actin (Sigma-Aldrich,
A5441, 1:5000) diluted in TBS. The next morning, membranes were washed three
times with TBS-T and once with TBS for five minutes. Membranes were incubated
with IRDye R© secondary antibodies to mouse (LI-COR, 926-32220, 680), rabbit (LI-
COR, 926-32211, 800CW), and goat (LI-COR, 926-32224, 680), respectively. Signals
were detected with the LICOR R© Odyssey Infrared Imaging System.
Immunohistochemistry
Fresh-frozen paraffin-embedded (FFPE) specimens derived from melanoma tu-
mors were obtained from the University of Munich under an approved Institutional
Review Board protocol. Antigen retrieval was performed by steaming the specimens
in IHC Select Citrate Buffer (Millipore) at 40 kPa for 15 min. The slides were blocked
with 10% FBS, 0.025% Triton-X-100, and 1% BSA in TBS for 1 h, then were incu-
bated with anti-MSX1 goat polyclonal antibodies (LS Bioscience, LS-2389) overnight
at 4◦C, and then with biotinylated horse anti-goat polyclonal antibodies (LS Bio-
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science, LS-D3) at room temperature for 50 min. Signal detection and amplification
was achieved with the Vectastain ABC-Alkaline Phosphatase (ABC-AP) Kit Stan-
dard (Vector Laboratories) according to the manufacturers instructions. Vector Red
Alkaline Phosphatase chromogen substrate (Vector Laboratories) was added for 3
min resulting in a red precipitate. Slides were mounted in Kaisers Glycerol Gelatin,
preheated to 50◦C and were evaluated by a dermatopathologist using brightfield mi-
croscopy.
Differentiation assays and staining
For neural differentiation, cells were seeded in four-well glass chamber slides coated
with 50 µg/ml ornithin (Sigma Aldrich) and 1 mg/ml laminin (Sigma Aldrich). Cells
were initially grown as an adherent monolayer in 254CF medium (Life Technologies).
At a confluence of 80-90%, the medium was switched to ENStem-ATM neuronal differ-
entiation medium (Millipore) with freshly added 2 mM glutamine (Life Technologies).
One half of the differentiation media was changed every other day. After 18 days,
cells were washed in PBS and fixed in 4% paraformaldehyde, then stained by anti-
neurofilament-L antibodies (Millipore, MAB1615SP). For smooth muscle cell- and
adipocytic differentiation, cells were cultured in four-well glass chamber slides coated
with fibronectin (1:1000). The smooth muscle cell differentiation media has been
previously described43. The StemPro R© Adipogenesis Differentiation Kit (Life Tech-
nologies, A10070-01) was used according to the manufacturers instructions. Smooth
muscle cell differentiation was assessed after 14 days by immunofluorescent staining
for smooth muscle actin (Sigma Aldrich, A2547). Adipocyte differentiation was de-
termined by oil-red-O-staining after 13 days as previously described 41. To detect
p75 expression, cells were washed in PBS and fixed in a 1:1 mixture of acetone and
ice-cold methanol. After incubation at -20◦C for 10 min, blocking was performed
with 2% BSA in PBS with 0.1% Tween20 (PBS-T). Subsequently, cells were incu-
bated with anti-p75 antibodies (The Wistar Institute, ME20.4)68 overnight at 4◦C.
Cells were washed 3 times in PBS-T and incubated with secondary antibodies con-
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jugated with Alexa Fluor-488 or -568 (Life Technologies) for 1 h in the dark. In
all cases, immunofluorescence was detected with a Nikon E600 upright microscope
(Nikon Instruments).
Reporter assays
The transcriptional activity of the human M-MITF promoter (hMIP) was assessed
in stably iMSX1-infected WM88 cells. Cells were seeded with 3.5 to 5 x 105 cells /
well in 6-well plates, and were transiently infected with 1000 ng of the firefly luciferase
promoter constructs pGL3-hMIP-2kb, 1kb and 0.5kb using 5 µl Lipofectamine2000
(Life Technologies). For internal normalization, the cells were co-transfected with 200
ng pRL-TK Renilla luciferase (Promega). 24 h after transfection, the expression of
MSX1 was either induced by adding 500 ng/µl doxycycline or left unaltered by adding
an equal amount of PBS. The activity of each promoter construct was measured 48 h
later using the Dual-Luciferase R© Reporter Assay System (Promega, E1910) accord-
ing to the manufacturers instructions. Cells were washed twice with 1X PBS and
actively lysed with 250 µl of 1X Passive Lysis Buffer with scraping. After removing
the cell debris, 20 µl of the lysates were combined with 100 µl of Luciferase Assay
Reagent II and assessed for firefly luciferase activity on NuncTM F96 MicroWell White
Polystyrene plates (Thermo ScientificTM, 12-566-02) in triplicate. Luminescence was
measured using a Wallac Victor 2 multilabel counter (PerkinElmer, 1420-032) using
manufacturer protocols. Renilla luciferase was measured with the addition of 100 µl
of Stop & Glo R© Reagent. Firefly luminescence values were normalized over Renilla
luciferase values to determine the normalized luciferase activity.
Microarrays
Total RNAs were extracted from melanocytes using a RNeasy kit (Qiagen). cD-
NAs were generated using oligo(dT) primers, fragmented, biotinylated and hybridized
to the Illumina HumanHT-12V4 expression Beadchip Arrays (Illumina). Raw data
were normalized, background-corrected and summarized using the R package lumi69.
To reduce false positives, unexpressed probes were removed, leaving 19,968 probes
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that were examined in all experiments described herein. The R package limma70,71
was employed for gene expression analysis to identify 493 differentially expressed
genes with a p value < 0.05. For MSX1 expression analysis in the publicly avail-
able dataset, we obtained the GSE12391 dataset from the GEO database (http:
//www.ncbi.nlm.nih.gov/geo/) and analyzed it using GEOs online tool GEO2R
(http://www.ncbi.nlm.nih.gov/geo/geo2r/). The R package limma71 was em-
ployed to assess the significance of gene expression differences among the groups of
samples.
Chromatin immunoprecipitation (ChIP)
ChIP was performed using a SimpleChIP R© Enzymatic Chromatin IP Kit (Cell
Signaling) according to the manufacturers instructions. 4 x 107 melanoma cells were
transfected with pCS2-3XFLAG-MSX1 and incubated for 48 h. The cells were fixed
for 10 min with 1% formaldehyde in culture medium, and then crosslinking was
quenched with glycine (final concentration 125 mM) for 5 min. After the cells were
lysed on ice and the nuclear fraction isolated, the nuclei were digested with micro-
coccal nuclease and sonicated using a Bioruptor R© Standard water bath sonicator
(Diagenode, B01010003) in 30 sec pulses for a total sonication time of 10 min to gen-
erate 150bp to 900bp (1 to 5 nucleosomes) chromatin fragments, analyzed by agarose
gel. Protein G magnetic beads were added after incubating 10 µg of chromatin with
2 µg anti-FLAG M2 (Stratagene, 200472) or control mouse IgG antibodies overnight.
Finally, the precipitated samples were analyzed using primer sequences specific to
the designated amplicons using quantitative PCR and were normalized to the input
sample. Primer sequences are listed in Table 5.2.
Animal experiments
All animal experiments were performed in accordance with Wistar IACUC pro-
tocol 112330 in NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ mice. Two days before injection,
5x105 cells were seeded into T75 flasks without the presence of puromycin. After two
days, the cells were washed with HBSS, trypsinized, and pelleted. For sub-cutaneous
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injections, 1x105 cells were resuspended in Growth Factor Reduced Matrigel (BD
Biosciences) diluted 1:1 in PBS (100 µl / mouse). Tumor growth was measured twice
weekly until tumor volumes reached 1000-1500 mm3 on average, measured by caliper.
For intravenous tail-vein injections, 1x105 cells were suspended in 100 µl of PBS. The
mice were euthanized by CO2. Mouse tumors and organs were kept in PBS on ice
until they were transferred to Prefer R© (Anatech, Ltd.) and fixed overnight at 4◦C,
then kept in 70% ethanol.
Statistics
All experiments were done in replicate samples and were repeated at least two
or three times for validation. Two-sample t-tests with equal or unequal variances
were used for data analysis. All statistical tests were performed under a two-sided
hypothesis with a two-tailed p-value of less than or equal to 0.05 to reject the null
hypothesis.
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